Trump’s pick for FDA to test ‘due diligence’ of Agency’s science

Bloomberg Law, November 25, 2024: Dr. Marty Makary has been named by Donald Trump to lead the FDA. The Johns Hopkins surgeon has been an outspoken critic of FDA’s relationships with industry and his appointment could shake up the status quo. NCHR and other experts are optimistic that Dr. Makary will encourage the agency to reduce conflicts of interest and hold industry to a higher standard for FDA approval of medical products and food safety.

Read More »

What Trump’s election win could mean for AI, climate and health

Nature, November 8, 2024: Nature magazine news article on the impact of Trump election includes views regarding health programs. NCHR asks if RFK Jr. stated plans to “reduce corporate greed” will be implemented, given the close ties between the first Trump Administration and the pharmaceutical industry.

Read More »

F.D.A. names a new chief of medical devices

New York Times, Oct 22, 2024: Michelle Tarver is the new director of CDRH, FDA medical device center, promoted from within the agency. We are hopeful that she will move CDRH to focus more on ensuring safe and effective medical devices, reversing the bias of former director Jeff Shuren. But given her expertise, why has the agency failed to warn Lasik patients as promised?

Read More »